MBX · XBRL financial data

MBX Biosciences financial statements, every quarter

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MBX's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	16,747	15,223*	22,405	17,724	19,270	19,759*	18,474	30,985
General and administrative	2,865	3,387*	4,124	4,081	4,656	6,036*	8,791	9,946
Total operating expenses	19,612	18,610*	26,529	21,805	23,926	25,795*	27,265	40,931
Operating income (loss)	(19,612)	(18,610)*	(26,529)	(21,805)	(23,926)	(25,795)*	(27,265)	(40,931)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—
Net income (loss)	(18,142)	(15,586)*	(23,880)	(19,411)	(21,618)	(22,062)*	(23,517)	(37,095)
Earnings per share, basic USD per share	(2.78)	—	(0.71)	(0.58)	(0.63)	(0.49)*	(0.50)	(0.78)
Earnings per share, diluted USD per share	(2.78)	—	(0.71)	(0.58)	(0.63)	(0.49)*	(0.50)	(0.78)
Weighted average shares, basic thousands of shares	6,516	—	33,412	33,446	34,199	44,866*	46,576	47,696
Weighted average shares, diluted thousands of shares	6,516	—	33,412	33,446	34,199	44,866*	46,576	47,696

Fiscal quarters (MBX's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	132,865	49,351	29,903	39,781	223,125	75,289	45,214	54,124
Marketable securities	144,198	212,798	210,883	185,125	168,548	298,416	394,763	364,457
Prepaid and other current assets	4,107	5,137	3,490	4,284	5,829	7,834	8,559	9,281
Total current assets	281,170	267,286	244,276	229,190	397,502	381,539	448,536	427,862
Property and equipment, net	1,033	1,080	1,509	1,730	2,004	2,735	3,133	4,663
Right-of-use asset	147	119	91	551	520	487	453	2,759
Total assets	282,400	268,535	245,926	231,522	400,076	385,144	452,701	435,909
Accounts payable	5,002	5,335	4,245	5,764	3,768	2,977	6,974	4,356
Accrued liabilities	5,752	5,545	6,106	5,854	8,140	12,346	7,415	18,673
Total current liabilities	10,920	11,051	10,481	11,756	12,062	15,495	14,567	23,660
Lease liability, non-current	44	0	—	512	469	424	377	2,710
Total liabilities	11,032	11,093	10,504	12,283	12,538	15,921	14,945	26,370
Accumulated deficit	(121,919)	(137,505)	(161,385)	(180,796)	(202,414)	(224,476)	(247,993)	(285,088)
Total stockholders' equity	271,368	257,442	235,422	219,239	387,538	369,223	437,756	409,539
Total liabilities and equity	282,400	268,535	245,926	231,522	400,076	385,144	452,701	435,909
Common shares outstanding (cover page) thousands of shares	33,417	33,424	33,424	33,594	44,902	47,510	47,598	48,160

Fiscal quarters (MBX's year ends in late December)

In thousands of dollars	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(18,142)	(15,586)*	(23,880)	(19,411)	(21,618)	(22,062)*	(23,517)	(37,095)
Stock-based compensation	1,192*	1,488*	1,839	1,937*	2,245*	2,656*	5,484	6,064*
Net cash from operating activities	(14,664)*	(16,037)*	(22,678)	(17,434)*	(21,536)*	(18,301)*	(20,208)	(22,622)*
Purchases of property and equipment	57*	92*	30	707*	399*	793*	437	901*
Net cash from investing activities	(100,788)*	(67,345)*	3,226	25,986*	17,056*	(129,973)*	(97,097)	29,210*
Proceeds from issuing common stock	—	—	—	—	—	year only	688,800	0*
Net cash from financing activities	235,814*	(132)*	4	1,326*	187,824*	438*	87,435	2,321*
Net change in cash	120,362*	(83,514)*	(19,448)	9,878*	183,344*	(147,836)*	(29,870)	8,909*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
MBX Biosciences	54,124	not reported	(22,622)*	48.2M	18.5 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	20,721	not reported	(2,213)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45,090	not reported	(4,589)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	165,896	not reported	(11,099)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	23,035	25,322	6,946*	37.9M	—	Q3 FY26 10-QSep 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.